ImmuCell Valuation
| ICCC Stock | USD 4.99 0.10 2.04% |
At this time, the firm appears to be undervalued. ImmuCell retains a regular Real Value of $7.24 per share. The prevalent price of the firm is $4.99. Our model calculates the value of ImmuCell from evaluating the firm fundamentals such as Current Valuation of 56.19 M, return on equity of -0.16, and Return On Asset of -0.0487 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that ImmuCell's price fluctuation is slightly risky at this time. Calculation of the real value of ImmuCell is based on 3 months time horizon. Increasing ImmuCell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ImmuCell is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ImmuCell Stock. However, ImmuCell's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.99 | Real 7.24 | Hype 5.0 | Naive 4.65 |
The real value of ImmuCell Stock, also known as its intrinsic value, is the underlying worth of ImmuCell Company, which is reflected in its stock price. It is based on ImmuCell's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ImmuCell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ImmuCell helps investors to forecast how ImmuCell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ImmuCell more accurately as focusing exclusively on ImmuCell's fundamentals will not take into account other important factors: ImmuCell Total Value Analysis
ImmuCell is currently forecasted to have valuation of 56.19 M with market capitalization of 32.08 M, debt of 16.69 M, and cash on hands of 11.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ImmuCell fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
56.19 M | 32.08 M | 16.69 M | 11.04 M |
ImmuCell Investor Information
About 40.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImmuCell has Price/Earnings (P/E) ratio of 195.0. The entity recorded a loss per share of 0.49. The firm had not issued any dividends in recent years. ImmuCell had 1:100 split on the 25th of July 1990. ImmuCell is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.ImmuCell Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ImmuCell has an asset utilization ratio of 39.88 percent. This indicates that the Company is making $0.4 for each dollar of assets. An increasing asset utilization means that ImmuCell is more efficient with each dollar of assets it utilizes for everyday operations.ImmuCell Ownership Allocation
The market capitalization of ImmuCell is $32.08 Million. ImmuCell secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.ImmuCell Profitability Analysis
The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (5.77 M) with profit before overhead, payroll, taxes, and interest of 7.65 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ImmuCell's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ImmuCell and how it compares across the competition.
About ImmuCell Valuation
The stock valuation mechanism determines ImmuCell's current worth on a weekly basis. Our valuation model uses a comparative analysis of ImmuCell. We calculate exposure to ImmuCell's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ImmuCell's related companies.ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Immucell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.
ImmuCell Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 7.7 M | |
| Quarterly Earnings Growth Y O Y | -0.634 |
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |